Researchers in Montreal have developed a temporary “smart tattoo” designed to detect micromelanomas at an invisible stage by mapping thermal variations on the skin. The technology, known as SMEAR-ULM, utilizes microneedles to place temperature-sensitive nanoparticles under the skin, offering a potential non-invasive alternative to traditional biopsies for early-stage skin cancer screening.
The Mechanics of the SMEAR-ULM System
The technology functions as a microscopic thermometer, addressing a long-standing challenge in dermatological diagnostics: how to identify tumors that are too small for clinical observation. According to research from the Institut national de la recherche scientifique (INRS) and the Université de Montréal, the system relies on the fact that cancerous cells consume more oxygen and nutrients than healthy tissue, resulting in localized heat production.
To capture these subtle metabolic signatures, the device uses microneedles to deposit specialized nanoparticles just below the skin’s surface. These particles form a temporary, painless network. When exposed to near-infrared light, the nanoparticles emit visible light, with the duration of the emission directly linked to the temperature of the surrounding skin.
The system then employs high-speed imaging to translate these thermal signals into a precise map. As detailed by the Université de Montréal, this thermo-dermoscopy approach achieves a submillimeter spatial resolution and a temperature sensitivity of less than one degree Celsius. By visualizing these minute thermal deviations, clinicians can identify lesions that are currently invisible to the naked eye.
Addressing Limitations in Clinical Diagnostics
Current diagnostic standards often require a lesion to reach a diameter of approximately five millimeters before clinicians initiate further, often invasive, investigations. This reliance on visual assessment can lead to both missed early-stage diagnoses and the performance of unnecessary biopsies.
Jinyang Liang, a professor at the INRS specializing in ultrafast imaging and biophotonics, emphasized the precision gap in current methods.
“On peut utiliser la température comme biomarqueur pour détecter les anomalies métaboliques dans ces minuscules micromélanomes,” a expliqué le professeur Jinyang Liang, de l’INRS. “On parle d’utiliser la température comme biomarqueur depuis longtemps, mais jusqu’à présent, on n’avait pas d’outil pour la mesurer avec précision.”
By providing a non-invasive, high-speed imaging tool, the researchers aim to catch the disease at a stage where it remains highly treatable. The technology was recently tested in animal models, where it successfully identified tumors that were only four days old—a stage at which they are typically undetectable by standard imaging techniques.
The research team focused on the integration of biophotonics to bridge the gap between biological metabolic activity and optical detection. By utilizing the specific thermal signature of cancerous cells, the SMEAR-ULM system seeks to overcome the limitations of current diagnostic imaging, which often relies on anatomical changes that occur only after a tumor has reached a significant size. The microneedle array is designed to be minimally invasive, ensuring that the patient experience is prioritized while maintaining the high sensitivity required for early detection.
Implications for Future Skin Cancer Screening
While the results in animal models are encouraging, the transition to human clinical use remains the next hurdle. Sylvain Meloche, a researcher at the Institut de recherche en immunologie et en cancérologie of the Université de Montréal, noted that the current model effectively mirrors genetic modifications found in human melanoma. This alignment is critical, as it suggests the thermal signatures detected in the animal models are representative of the metabolic profiles that would be observed in human skin cancers.
The potential shift in clinical practice is significant. If validated for human use, the SMEAR-ULM device could reduce the frequency of invasive procedures while increasing the sensitivity of early-stage screening. As reported by Vibration, the technology’s ability to map thermal zones with such high accuracy could transform the standard of care for patients at high risk of developing melanoma, the most aggressive form of skin cancer.
The researchers are now focusing on the necessary steps to move beyond preclinical trials. The goal is to refine the tool into a diagnostic instrument that is both accessible and rapid, potentially offering a new, non-invasive standard for dermatologists. As the incidence of melanoma continues to rise in Canada, the development of such tools is increasingly viewed as a priority for public health initiatives.
While the technical capabilities of the SMEAR-ULM system show promise, medical professionals emphasize that any diagnostic screening technology must undergo rigorous clinical validation before it can be considered a standard of care. Patients concerned about changes in their skin should continue to consult with qualified dermatologists to undergo established screening protocols. The integration of this technology into a clinical setting will depend on future studies confirming its efficacy, safety, and reliability across diverse patient populations. Current research remains focused on the optimization of the nanoparticle delivery system and the refinement of the high-speed imaging algorithms to ensure consistency in varying clinical environments.